Abstract 16P
Background
This study aimed to assess preferences of patients and healthcare practitioners (HCPs) regarding treatment attributes for early-stage triple-negative breast cancer (TNBC) in the Asia-Pacific region.
Methods
A discrete choice experiment (DCE) was conducted in Australia, Korea, Philippines, Japan, and Taiwan, with 115 patients who self-reported a diagnosis of early-stage TNBC and 86 HCPs. Key attributes relevant to TNBC treatment decision-making were verified through qualitative interviews with clinical experts. A D-efficient fractional-factorial design was employed to create 15 online choice sets with seven key attributes: disease-free/event-free survival (DFS/EFS), pathological complete response (pCR), chance of undergoing breast conserving surgery after receiving anticancer treatment, febrile neutropenia, peripheral sensory neuropathy, diarrhea, and irreversible endocrine-related adverse events (AEs) requiring lifelong medication. A mixed logit model was used to estimate preference weights for attribute levels, which were then used to compute the relative importance score (RIS) for each attribute.
Results
Median age of patients were 44.0 (interquartile range 38.0-56.5) years. 68% of patients were married, 77% had children, 40% employed full-time and 70% had a college degree. 46% of patients were diagnosed below the age of 40. Among the HCPs, 58% were medical oncologists and the remaining breast or general surgeons. PCR, DFS/EFS, and peripheral sensory neuropathy were the three most important attributes in both HCP and patient groups. pCR had the highest weighted preference among patients and HCPs (RIS, 28.46 and 32.86, respectively). In general, patients assigned greater weight to safety attributes compared to HCPs, while HCPs assigned more weight to efficacy attributes than patients. Surgeons assigned more weight for irreversible endocrine-related AEs than medical oncologists (RIS, 14.4 vs. 5.4).
Conclusions
Overall, patients and HCP preferences were aligned in ranking for efficacy and safety attributes tested. Differences in preferences within the regions were notable.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IQVIA Solutions Asia Pte. Ltd.
Funding
MSD International GmbH, Singapore Branch.
Disclosure
J. Lai, Y. Antill, K.H. Jung, C. Shimizu, M.L. Abesamis Tiambeng: Financial Interests, Personal, Advisory Board: MSD. E.M. Tan, S. Qu: Financial Interests, Personal, Full or part-time Employment, IQVIA was commissioned to carry out this study.: IQVIA Asia Pacific. C. Spiteri, S.Y. Ihm, D. Hsu: Financial Interests, Personal, Full or part-time Employment: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract